Register Now
Why register?
 The leading web portal for pharmacy resources, news, education and careers July 29, 2014
Pharmacy Choice - News - Generic Drugs - July 29, 2014

Pharmacy News

 Generic Drugs
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 42     Next >>     Go To Page:

7/29/14 - Central Europe Generic and Innovative Drugs Market 2018 Forecasts
What is the value of the generic and innovative drugs market in Poland, in Romania, Slovakia, the Czech Republic, Hungary and Bulgaria? Generic and innovative drugs market in Central Europe, comparative analysis, reimbursement policies and development forecasts for 2014-2018 is a comprehensive guide to the market and all its conditions and variable
7/29/14 - Medicines360 and Actavis Secures FDA Acceptance for Filing of NDA for Levosert IUD [Manufacturing Close - Up]
Medicines360 and Actavis reported that the U.S. Food and Drug Administration has accepted for filing Medicines360's New Drug Application for Levosert, a hormonal intrauterine contraceptive for use by women to prevent pregnancy. According to a media release, in June 2013, Medicines360 and Actavis announced that they had entered into a partnership th
Pfizer Inc. reported financial results for second-quarter 2014. At the beginning of fiscal year 2014, the company began managing its commercial operations through a new global commercial structure consisting of three operating segments: the Global Innovative Pharmaceutical segment; the Global Vaccines, Oncology and Consumer Healthcare segment; and.
7/29/14 - World Biosimilars Market Value Exceed $262 Billion by 2019 Says a New Report Available at
Using detailed company data, financial analysis, corporate strategy, and market trends analysis, GlobalData provides in-depth analysis of the current and future growth drivers of the biosimilars industry. Overview of Key Players in Global Biosimilars Market:? Hospira? Actavis? Pfizer? Sandoz? Stada Arzneimittel? Gedeon Richter? Kyowa
7/28/14 - 'This year is going to be a challenging one for US business' [DNA : Daily News & Analysis (India)]
Your first quarter numbers for US are almost flat at 9.33%. Is there any specific reason? I feel things are really slow as per FDA approvals and that is why, we are seeing slower growth.
7/28/14 - Abbott to Sell its Developed Markets Branded Generics Pharmaceuticals Business to Mylan
By a News Reporter-Staff News Editor at Pharma Business Week Abbott announced that it will sell its developed markets branded generics pharmaceuticals business to Mylan for equity ownership of a newly formed entity that will combine Mylan's existing business and Abbott's developed markets pharmaceuticals business, and will be a publicly traded...
7/28/14 - Agency Information Collection Activities; Announcement of Office of Management and Budget Approval; Animal Generic Drug User Fee Cover Sheet
SUMMARY: The Food and Drug Administration is announcing that a collection of information entitled "Animal Generic Drug User Fee Cover Sheet" has been approved by the Office of Management and Budget under the Paperwork Reduction Act of 1995.. FOR FURTHER INFORMATION CONTACT: FDA PRA Staff, Office of Operations, Food and Drug Administration, 8455 Col
7/28/14 - Changes in generic pill color and shape disrupt use
By a News Reporter-Staff News Editor at Cardiovascular Week Boston, MA- Generic versions of the same prescription drug are clinically interchangeable but often look different depending on the manufacturer. Studying a national cohort of patients who recently suffered a heart attack, researchers from Brigham and Women's Hospital have found that var
7/28/14 - Coherus Announces Initiation Of Phase 3 Trial Of CHS-0214 Investigational Etanercept Biosimilar In Chronic Plaque Psoriasis RaPsOdy
By a News Reporter-Staff News Editor at Biotech Business Week Coherus BioSciences>, Inc. announced the start of its Phase 3 trial of CHS-0214, a proposed biosimilar of etanercept, in chronic plaque psoriasis. "It represents a pivotal study in the global clinical development for CHS-0214 and, if positive, will provide supp
7/28/14 - Depomed Announces District Court Order in ANDA Litigation
By a News Reporter-Staff News Editor at Pharma Business Week Depomed, Inc. announced that on July 17, 2014, Judge Joel A. Pisano of the United States District Court for the District of New Jersey entered an order preliminarily enjoining Actavis Elizabeth LLC and Actavis Inc. from marketing a generic version of Gralise prior to the Court's issu
7/28/14 - Gilead Announces New Agreement with Medicines Patent Pool for Access to Medicines in Developing World Countries
Release date- 25072014- MELBOURNE, Australia- Gilead Sciences, Inc. announced today at the 20th International AIDS Conference in Melbourne, Australia, a new agreement with the Medicines Patent Pool to expand access to Gilead's investigational drug tenofovir alafenamide for HIV and hepatitis B, contingent on the medicine's U.S. regulatory approval.
7/28/14 - Leading U.S. Proxy Advisory Firm Supports Teva Nominees and Other Shareholders' Meeting Proposals
By a News Reporter-Staff News Editor at Pharma Business Week Teva Pharmaceutical Industries Ltd., reported that ISS Proxy Advisory Services, the leading U.S. independent proxy advisory firm, recommended that shareholders vote in favor of all Teva nominees for director and for each of the other proposals on the agenda for consideration at the Comp
7/28/14 - Mapi Pharma postpones and halves Nasdaq IPO [Globes, Tel Aviv, Israel :: ]
July 28 Drug developer Mapi Pharma, which was scheduled to complete a $37 million financing round at the end of last week, published a revised prospectus on Friday for raising only $20 million. Mapi Pharma is not bringing a great dream to its offering, while on the other hand, it does not present a well-oiled generic operation with reliable reven
7/28/14 - New Findings from RAND in the Area of Medicare and Medicaid Described (Impact of Medicare Part D Plan Features on Use of Generic Drugs)
By a News Reporter-Staff News Editor at Managed Care Weekly Digest Fresh data on Medicare and Medicaid are presented in a new report. According to news reporting from Pittsburgh, Pennsylvania, by NewsRx journalists, research stated, "Little is known about how Medicare Part D plan features influence choice of generic versus brand drugs. Generic co
7/28/14 - Research and Markets Adds Report: The World Market for Biosimilars, 4th Edition (EPO, G-CSF, HGH, Insulin, Interferon alpha, mAbs, Others) [Health & Beauty Close - Up]
Research and Markets has announced the addition of the "The World Market for Biosimilars, 4th Edition" report to its offerings. In a release, Research and Markets noted that report highlights include:. -Beijing Four Rings Biopharmaceutical Co Ltd.
7/28/14 - Wockhardt's plant may soon get out of regulatory woes [DNA : Daily News & Analysis (India)]
Mumbai: Wockhardt Ltd, which denied stake-sale rumours on Friday following an unusual spurt in its stock price, is in the final stages of receiving much-awaited regulatory approvals for its Chikalthana unit in Maharashtra. When contacted by dna regarding possible audits, FDA spokesperson Christopher Kelly said, "The Wockhardt facilities that were p
7/26/14 - Biocon files first new drug applications [DNA : Daily News & Analysis (India)]
Mumbai: Bangalore- based Biocon on Friday said it has filed its first abbreviated new drug applications targeting the US generics market during the June quarter. The biotechnology company has reported a 9% increase in its net profit at Rs 102.91 crore for the quarter ended June 2014 compared with Rs 93.5 crore posted during the corresponding period
7/25/14 - CPhI South America 2014 Launches with Generics Showing Huge Growth
Three of the top 25 countries for pharmaceutical sales are now exploring the South America market as a result of increased healthcare investment for the burgeoning middle class. Host of CPhI South America, Brazil is expected to become the fourth biggest pharmaceutical market in the world by 2022 with its value predicted to be USD 61.05 billion.
7/25/14 - Germany : FDA accepts Sandoz application for biosimilar filgrastim [TendersInfo (India)]
Sandoz, a Novartis Group company, announced today that the US Food and Drug Administration has accepted its Biologics License Application for filgrastim, which was filed under the new biosimilar pathway created in the Biologics Price Competition and Innovation Act of 2009. "This filing acceptance represents a significant step toward making high-qu
7/25/14 - IGI Laboratories Announces Change To Its Board Of Directors [Global Data Point]
About IGI Laboratories, Inc.&# x0D;. IGI Laboratories is a specialty generic drug development and manufacturing company. Our mission is to be a leading player in the specialty generic prescription drug market.&# x0D;.
7/25/14 - IGI Laboratories Announces Second Quarter 2014 Results [Global Data Point]
?Total revenues generated from the sale of IGI label generic topical pharmaceutical products for the three and six months ended June 30, 2014 were $3.4 million, and $6.3 million, respectively, increases of 146% and 127% over the same periods in 2013, respectively&# x0D;. ?IGI filed an additional ANDA, under a joint development agreement with Im
The agreement between Medicine Patent Pool and Gilead Sciences of the US on HIV drug is expected to provide an opportunity for Indian pharmaceutical companies. Manufacturers in India can develop generic versions of tenofovir alafenamide for 112 countries. The MPP-Gilead agreement intends to expedite production of generic version of TAF.
7/25/14 - United Kingdom : Hikma agrees to acquire Ben Venue manufacturing site adding R&D capabilities and capacity [TendersInfo (India)]
Hikma Pharmaceuticals PLC, the fast growing multinational pharmaceutical group, today announces that it has agreed with Ben Venue Laboratories, Inc., part of the Boehringer Ingelheim Group of Companies, to acquire substantially all of the assets of their generic injectables manufacturing site in Bedford, Ohio. No incremental consideration is payabl
7/24/14 - AmerisourceBergen Reports Third Quarter Fiscal Year 2014 Results
AmerisourceBergen Corporation today reported that in its fiscal year 2014 third quarter ended June 30, 2014, adjusted diluted earnings per share from continuing operations increased 29.5% percent to $1.01. Revenue increased 38.5 percent to $30.3 billion in the quarter. We delivered very strong performance in our June quarter, driven by the onboa
7/24/14 - Beximco Pharmaceuticals Confident In Meeting Full-Year Targets
The Dhaka, Bangladesh- based generic pharmaceuticals manufacturer posted a pretax profit of BDT1.02 billion, up from BDT955.6 million, as revenue rose to BDT5.32 billion from BDT4.97 billion. Beximco said that although its export sales had decreased during the first half compared to export sales, it is hopeful of achieving its expected sales for th
Articles(s): 1 - 25 of 42     Next >>     Go To Page:

© 2014 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry


Lupus: What You Need to Know
This lesson is supported by:
West Virginia Best Practice Prescribing & Drug Diversion Training
This lesson is supported by:

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...

Websites »
Copyright © 2009 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement